SAN DIEGO, Sept. 7, 2021 /PRNewswire/ -- Aethlon
Medical, Inc. (Nasdaq: AEMD), a medical technology company focused
on developing products to diagnose and treat life and organ
threatening diseases, today announced that it will be presenting at
the H.C. Wainwright 23rd Annual Global Investment
Virtual Conference. The conference is being held virtually
from September 13-15, 2021.
Charles J. Fisher, M.D., Chief
Executive Officer, will present an overview of Aethlon Medical the
conference. The presentation will be available on-demand beginning
Monday, September 13 at 7:00 AM EDT at the link below and will be
archived for 90 days. It will also be available on the Aethlon
website. In addition to the overview presentation, Dr. Fisher will
be hosting virtual one-on-one meetings at the conference on
Monday, September 13.
Event: H.C. Wainwright 23rd Annual
Global Investment Conference (Virtual Conference)
Date: September 13,
2021
Time: 7:00 AM EDT
Location: Virtual Conference
Company Webcasting Link:
https://journey.ct.events/view/11f097cf-439f-49c7-9a8c-10f0dfa0fe5e
About Aethlon and the Hemopurifier®
Aethlon is focused on addressing unmet needs in global health.
The Aethlon Hemopurifier is a clinical-stage immunotherapeutic
device designed to combat cancer and life-threatening viral
infections. In cancer, the Hemopurifier is designed to deplete the
presence of circulating tumor-derived exosomes that promote immune
suppression.
The Hemopurifier is an FDA designated "Breakthrough Device"
related to the treatment of individuals with advanced or metastatic
cancer who are either unresponsive to or intolerant of standard of
care therapy, and with cancer types in which exosomes have been
shown to participate in the development or severity of the disease.
Under an Investigational Device Exemption (IDE) application, in
October 2019, the FDA approved an
Early Feasibility Study (EFS), which is the device equivalent of a
Phase 1 clinical trial for a drug or biologic, in a single center,
open label trial in 10 to 12 subjects. The study is
evaluating the HEMOPURIFIER® for reducing cancer-associated
exosomes prior to the administration of standard-of-care
pembrolizumab (KEYTRUDA®), which is a first-line therapy for
patients with recurrent and/or metastatic squamous cell carcinoma
of the head and neck. The EFS is being conducted at the
University of Pittsburgh Medical Center
Hillman Cancer Center.
The Hemopurifier also holds a Breakthrough Device designation
related to life-threatening viruses that are not addressed with
approved therapies. In June
2020, the FDA approved an amendment to the Company's
existing open IDE for the Hemopurifier in life threatening viral
infections to allow for the treatment of patients with
SARS-CoV-2/COVID-19 infection. This will allow for up to 40
of these patients to be treated under a new Early Feasibility Study
protocol at up to 20 clinical sites in the U.S.
Aethlon also owns 80% of Exosome Sciences, Inc., which is
focused on the discovery of exosomal biomarkers to diagnose and
monitor cancer and neurological disease progression. Additional
information can be found online at www.AethlonMedical.com and
www.ExosomeSciences.com.
Forward Looking Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934 that involve
risks and uncertainties. Statements containing words such as "may,"
"believe," "anticipate," "expect," "intend," "plan," "project,"
"will," "projections," "estimate," "potentially" or similar
expressions constitute forward-looking statements. Such
forward-looking statements are subject to significant risks and
uncertainties and actual results may differ materially from the
results anticipated in the forward-looking statements. These
forward-looking statements are based upon Aethlon's current
expectations and involve assumptions that may never materialize or
may prove to be incorrect. Factors that may contribute to such
differences include, without limitation, the Company's ability to
enroll patients in and successfully complete trials in the Early
Feasibility Studies in head and neck cancer and in COVID-19
patients, the Company's ability to successfully treat patients
under any Emergency Use pathway, the Company's ability to
successfully complete development of its Hemopurifier, the
Company's ability to raise additional funds, and other potential
risks. The foregoing list of risks and uncertainties is
illustrative, but is not exhaustive. Additional factors that could
cause results to differ materially from those anticipated in
forward-looking statements can be found under the caption "Risk
Factors" in the Company's Annual Report on Form 10-K for the year
ended March 31, 2021, and in the
Company's other filings with the Securities and Exchange
Commission, including its quarterly Reports on Form 10-Q. All
forward-looking statements contained in this press release speak
only as of the date on which they were made. Except as may be
required by law, the Company does not intend, nor does it undertake
any duty, to update this information to reflect future events or
circumstances.
Company Contact:
Jim
Frakes
Chief Financial Officer
Aethlon Medical, Inc.
858-459-7800 x3300
Jfrakes@aethlonmedical.com
Media Contact:
Tony
Russo, Ph.D.
Russo Partners, LLC
tony.russo@russopartnersllc.com
212-845-4251
Investor Contact:
Susan
Noonan
S.A. Noonan Communications, LLC
susan@sanoonan.com
212-966-3650
View original
content:https://www.prnewswire.com/news-releases/aethlon-medical-to-present-at-the-hc-wainwright-23rd-annual-global-investment-conference-301370027.html
SOURCE Aethlon Medical, Inc.